Ampio Pharmaceuticals has announced results of a Phase III study of its anti-inflammatory drug Ampion. Study participants, 329 patients with osteoarthritis, reported an average 40% reduction in knee pain, along with significant improvement in knee function and quality of life, according to the company. Ampion is a new biologic drug being developed as a non-steroidal injection for the treatment of diseases involving inflammation. It is derived from a molecule (DA-DKP) that is believed to reduce inflammation by suppressing pro-inflammatory cytokine production in T-cells. Selection of the optimal dose for a second Phase III trial will be decided in consultation with the Food and Drug Administration. Read a news report on the findings here.